Paul Basciano

724 total citations
26 papers, 523 citations indexed

About

Paul Basciano is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Paul Basciano has authored 26 papers receiving a total of 523 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 8 papers in Oncology and 7 papers in Hematology. Recurrent topics in Paul Basciano's work include Platelet Disorders and Treatments (7 papers), Tryptophan and brain disorders (4 papers) and Glycosylation and Glycoproteins Research (3 papers). Paul Basciano is often cited by papers focused on Platelet Disorders and Treatments (7 papers), Tryptophan and brain disorders (4 papers) and Glycosylation and Glycoproteins Research (3 papers). Paul Basciano collaborates with scholars based in United States, Canada and Australia. Paul Basciano's co-authors include James B. Bussel, Richard A. Bernstein, Jared Knopman, Theodore E. Warkentin, Lillian L. Siu, Karen A. Gelmon, Jayesh Desai, Penny Phillips, Waleed Ghanima and Paul J. Christos and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Paul Basciano

24 papers receiving 521 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Paul Basciano United States	11	189	121	115	108	96	26	523
Mariaelvy Bianchini Germany	9	69 0.4×	48 0.4×	66 0.6×	166 1.5×	98 1.0×	13	385
Mary E.W. Collier United Kingdom	15	255 1.3×	29 0.2×	74 0.6×	88 0.8×	257 2.7×	28	558
Carl Högberg Sweden	12	184 1.0×	22 0.2×	87 0.8×	165 1.5×	159 1.7×	18	466
Marta Miguel Turu Spain	13	58 0.3×	80 0.7×	48 0.4×	130 1.2×	196 2.0×	22	561
Saskia N. I. von Ungern‐Sternberg Germany	9	55 0.3×	43 0.4×	71 0.6×	115 1.1×	164 1.7×	10	369
Viola Lorenz Germany	11	203 1.1×	34 0.3×	60 0.5×	70 0.6×	101 1.1×	13	462
Elena Ninci Germany	9	54 0.3×	54 0.4×	87 0.8×	104 1.0×	107 1.1×	10	324
Martina Gogarty Ireland	14	92 0.5×	24 0.2×	97 0.8×	188 1.7×	176 1.8×	18	506
Alexia Buzzonetti Italy	14	45 0.2×	61 0.5×	231 2.0×	280 2.6×	116 1.2×	30	615

Countries citing papers authored by Paul Basciano

Since Specialization

Citations

This map shows the geographic impact of Paul Basciano's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Basciano with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Basciano more than expected).

Fields of papers citing papers by Paul Basciano

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Basciano. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Basciano. The network helps show where Paul Basciano may publish in the future.

Co-authorship network of co-authors of Paul Basciano

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Basciano. A scholar is included among the top collaborators of Paul Basciano based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Basciano. Paul Basciano is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Moy, Ryan H., Brian Madajewski, A Petrone, et al.. (2024). 504MO Phase I study of the PKMYT1 inhibitor lunresertib (lunre) in combination with FOLFIRI in advanced gastrointestinal (GI) cancers (MINOTAUR study). Annals of Oncology. 35. S201–S201. 2 indexed citations

Carneiro, Benedito A., Ezra Y. Rosen, Elisa Fontana, et al.. (2024). 619MO Camonsertib (cam) monotherapy in patients (pts) with advanced cancers harboring ATM loss-of-function (LoF). Annals of Oncology. 35. S496–S496.

Paz-Ares, L., Mariano Provencio, José Trigo, et al.. (2021). P15.06 Safety of BMS-986012, an Anti–Fucosyl-GM1 Monoclonal Antibody Plus Platinum/Etoposide in Untreated Extensive-Stage SCLC. Journal of Thoracic Oncology. 16(3). S345–S346. 2 indexed citations

Drake, Charles G., Melissa L. Johnson, Alexander I. Spira, et al.. (2020). Personalized viral-based prime/boost immunotherapy targeting patient-specific or shared neoantigens: Immunogenicity, safety, and efficacy results from two ongoing phase I studies.. Journal of Clinical Oncology. 38(15_suppl). 3137–3137. 8 indexed citations

Luke, Jason J., Josep Tabernero, Anthony M. Joshua, et al.. (2019). BMS-986205, an indoleamine 2, 3-dioxygenase 1 inhibitor (IDO1i), in combination with nivolumab (nivo): Updated safety across all tumor cohorts and efficacy in advanced bladder cancer (advBC).. Journal of Clinical Oncology. 37(7_suppl). 358–358. 44 indexed citations

Fakih, Marwan, Wael A. Harb, Daruka Mahadevan, et al.. (2019). SPICE, a phase I study of enadenotucirev in combination with nivolumab in tumours of epithelial origin: Analysis of the metastatic colorectal cancer patients in the dose escalation phase. Annals of Oncology. 30. v231–v231. 7 indexed citations

Johnson, Melissa L., Alexander I. Spira, David P. Carbone, et al.. (2019). First Results of Phase I/II Studies Evaluating Viral Vector-Based Heterologous Prime/Boost Immunotherapy Against Predicted HLA Class I Neoantigens Demonstrate CD8 T Cell Responses In Patients with Advanced Cancers. Annals of Oncology. 30. xi34–xi34. 2 indexed citations

Siu, Lillian L., Karen A. Gelmon, Quincy S. Chu, et al.. (2017). Abstract CT116: BMS-986205, an optimized indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, is well tolerated with potent pharmacodynamic (PD) activity, alone and in combination with nivolumab (nivo) in advanced cancers in a phase 1/2a trial. Cancer Research. 77(13_Supplement). CT116–CT116. 71 indexed citations

Chu, Quincy S., C. van Herpen, Natasha B. Leighl, et al.. (2017). Initial results of BMS-986012, a first-in-class fucosyl-GM1 mAb, in combination with nivolumab, in pts with relapsed/refractory (rel/ref) small-cell lung cancer (SCLC). Annals of Oncology. 28. v539–v539. 5 indexed citations

10.

Chu, Quincy S., Ben Markman, Natasha B. Leighl, et al.. (2016). A phase 1/2 trial of a monoclonal antibody targeting fucosyl GM1 in relapsed/refractory small cell lung cancer (SCLC): Safety and preliminary efficacy. Annals of Oncology. 27. vi494–vi494. 3 indexed citations

11.

Basciano, Paul, Alessandro Pecci, Elisa Civaschi, et al.. (2014). β‐1 tubulin R307H SNP alters microtubule dynamics and affects severity of a hereditary thrombocytopenia. Journal of Thrombosis and Haemostasis. 13(4). 651–659. 15 indexed citations

12.

Bussel, JB, et al.. (2014). Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than two years duration. Haematologica. 99(7). 1264–1271. 64 indexed citations

13.

Warkentin, Theodore E., Paul Basciano, & Richard A. Bernstein. (2013). Spontaneous Heparin-Induced Thrombocytopenia Syndrome: Two New Cases and a Proposal For Defining This Disorder. Blood. 122(21). 2328–2328.

14.

Elstrom, Rebecca, et al.. (2012). Rituximab Combined with 3 Cycles of High Dose Dexamethasone Improves Response in Patients with Newly-Diagnosed, Persistent, and Chronic Immune Thrombocytopenia (ITP). Blood. 120(21). 3345–3345. 1 indexed citations

15.

Basciano, Paul, James B. Bussel, Zeeshan Hafeez, Paul J. Christos, & Paraskevi Giannakakou. (2012). The beta 1 tubulin R307H single nucleotide polymorphism is associated with treatment failures in immune thrombocytopenia (ITP). British Journal of Haematology. 160(2). 237–243. 22 indexed citations

16.

Viny, Aaron D., Paul Basciano, Mary Ann Howland, et al.. (2012). Hemorrhagic complications associated with dabigatran use. Clinical Toxicology. 50(9). 854–857. 41 indexed citations

17.

Basciano, Paul & James B. Bussel. (2012). Thrombopoietin-receptor agonists. Current Opinion in Hematology. 19(5). 392–398. 34 indexed citations

18.

Basciano, Paul, Robert D. Williams, P. Damiani, et al.. (2004). Actin‐dependent motility of melanosomes from fish retinal pigment epithelial (RPE) cells investigated using in vitro motility assays. Cell Motility and the Cytoskeleton. 58(2). 71–82. 13 indexed citations

19.

Basciano, Paul, et al.. (2002). Actin‐dependent, Retrograde Motility of Surface‐attached Beads and Aggregating Pigment Granules in Dissociated Teleost Retinal Pigment Epithelial Cells. Pigment Cell Research. 15(3). 184–191. 6 indexed citations

20.

Basciano, Paul, et al.. (2001). Effects of the Actin‐Stabilizing Drug, Jasplakinolide, on Pigment Granule Motility in Isolated Retinal Pigment Epithelial (RPE) Cells of Green Sunfish, Lepomis cyanellus. Pigment Cell Research. 14(1). 14–22. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact